Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | FAP | Q12884 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19745369 | 0.98 | EPHX1 (0.59) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 | |
| SCHEMBL1522063 | 0.87 | — | — | |
| SCHEMBL19757607 | 0.83 | EPHX1 (0.65) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 | |
| SCHEMBL3184451 | 0.83 | NAAA (0.66) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 | |
| SCHEMBL61529 | 0.82 | NAAA (0.59) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 | |
| SCHEMBL15865900 | 0.82 | EPHX1 (0.59) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 | |
| SCHEMBL1449384 | 0.82 | EPHX1 (0.59) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 | |
| SCHEMBL5855995 | 0.80 | EPHX1 (0.57) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 | |
| SCHEMBL16308968 | 0.80 | EPHX1 (0.57) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 | |
| SCHEMBL19302833 | 0.80 | EPHX1 (0.57) | EPHX1HDAC6HDAC8SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093683-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170044183-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9533963-B2 | Alkylamidothiazoles, cosmetic or dermatological preparations containing said alkylamidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin | BEIERSDORF AG (DE) | 2017-01-03 | — | — | US | disclosed |
| US-20140121250-A1 | ALKYLAMIDOTHIAZOLES, COSMETIC OR DERMATOLOGICAL PREPARATIONS CONTAINING SAID ALKYLAMIDOTHIAZOLES, AND USE THEREOF TO COMBAT OR PREVENT UNDESIRED PIGMENTATION OF THE SKIN | BEIERSDORF AG (DE) | 2014-05-01 | — | — | US | disclosed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | disclosed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | disclosed |
| US-5212312-A | Cationic | CIBA-GEIGY AG (CH) | 1993-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044183-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | EPHX1 283/4885HDAC6 1342/4885HDAC8 816/4885 |
| US-10093683-B2 | Factor XIa inhibitors | F11, F12, SERPINC1 | EPHX1 291/4885HDAC6 1482/4885HDAC8 885/4885 |
| US-20140121250-A1 | ALKYLAMIDOTHIAZOLES, COSMETIC OR DERMATOLOGICAL PREPARATIONS CONTAINING SAID ALKYLAMIDOTHIAZOLES, AND USE THEREOF TO COMBAT OR PREVENT UNDESIRED PIGMENTATION OF THE SKIN | TYR, PAH, NAT1 | EPHX1 2204/4885HDAC6 389/4885HDAC8 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.